2017-06-16

Immunovia AB announces timetable for listing on Nasdaq Stockholm's main market

LUND, Sweden - The Board of Directors of Immunovia AB today announces timetable for the application for listing of the company's shares on Nasdaq Stockholm's main market. Immunova's shares are currently traded on Nasdaq First North under the ticker IMMNOV.

The company’s preparations of internal processes to meet the requirements on the main market are expected to be completed in September. After that, Nasdaq's process is expected to be initiated and Immunovia anticipates that listing on the main market will begin by the end of the year.

"The company is progressing rapidly according to plan, and the future market introduction of IMMrayTM PanCan-d, the company's test for previous detection of pancreatic cancer, is attracting a lot of interest both in Sweden and internationally. Listing Immunova's shares on Nasdaq Stockholm's main market is the next step to gain access to the international capital market that enables more institutional investors to become owners," Mats Grahn, CEO of Immunovia, comments.


For more information, please contact:

Mats Grahn

Chief Executive Officer, CEO, Immunovia

Tel.: +46-70-5320230

Email: mats.grahn@immunovia.com


About Immunovia

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)

This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact person set out above on 16 June 2017 at 8.30 CET.

Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.

###